Sulbactam-Durlobactam for Carbapenem-Resistant Acinetobacter baumannii in a Child: A Novel Application of Adult Pharmacokinetics.

There are limited antimicrobial options for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). Sulbactam-durlobactam was recently approved for the treatment of CRAB in patients 18 years and older. However, CRAB infections can have mortality rates up to 80% in the intensive care unit. We describe the successful novel use of sulbactam-durlobactam in a pediatric patient using available adult pharmacokinetic data and preliminary pediatric dosing suggestions from a phase 1b trial.